rs878853922

Variant names:

• chr17-31200420-A-G
• rs878853922
• NM_001042492.3:c.889-2A>G

Your query was ambiguous. Multiple possible variants found:

• chr17-31200420-A-G
• chr17-31200420-A-T

Variant summary

Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1_Moderate PM2 PP5_Very_Strong

The NM_001042492.3(NF1):​c.889-2A>G variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).

• Frequency: Genomes: not found (cov: 32)
• Consequence: NF1 NM_001042492.3 splice_acceptor, intron
• Scores: Splicing: ADA: 1.000
• Clinical Significance: Pathogenic criteria provided, multiple submitters, no conflicts P:9
• Conservation: PhyloP100: 8.58
• Publications: 4 publications found

Genes affected

NF1 (HGNC:7765): (neurofibromin 1) This gene product appears to function as a negative regulator of the ras signal transduction pathway. Mutations in this gene have been linked to neurofibromatosis type 1, juvenile myelomonocytic leukemia and Watson syndrome. The mRNA for this gene is subject to RNA editing (CGA>UGA->Arg1306Term) resulting in premature translation termination. Alternatively spliced transcript variants encoding different isoforms have also been described for this gene. [provided by RefSeq, Jul 2008]

NF1 Gene-Disease associations (from GenCC):

• neurofibromatosis type 1

  Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), ClinGen, PanelApp Australia, G2P, Genomics England PanelApp
• neurofibromatosis-Noonan syndrome

  Inheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Genomics England PanelApp, PanelApp Australia
• Moyamoya disease

  Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
• hereditary pheochromocytoma-paraganglioma

  Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
• familial ovarian cancer

  Inheritance: AD Classification: NO_KNOWN Submitted by: ClinGen

ACMG classification

Our verdict: Pathogenic. The variant received 12 ACMG points.

• PVS1: Splicing +-2 bp (donor or acceptor) variant, product NOT destroyed by NMD, known LOF gene, truncates exone, which is 0.020422535 fraction of the gene. No cryptic splice site detected. Exon removal is inframe change.
• PM2: Very rare variant in population databases, with high coverage
• PP5: Variant 17-31200420-A-G is Pathogenic according to our data. Variant chr17-31200420-A-G is described in ClinVar as Pathogenic. ClinVar VariationId is 237610.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
NF1	NM_001042492.3	c.889-2A>G		splice_acceptor_variant, intron_variant	Intron 8 of 57	ENST00000358273.9	NP_001035957.1
NF1	NM_000267.4	c.889-2A>G		splice_acceptor_variant, intron_variant	Intron 8 of 56		NP_000258.1
NF1	NM_001128147.3	c.889-2A>G		splice_acceptor_variant, intron_variant	Intron 8 of 14		NP_001121619.1

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
NF1	ENST00000358273.9	c.889-2A>G		splice_acceptor_variant, intron_variant	Intron 8 of 57	1	NM_001042492.3	ENSP00000351015.4

Frequencies

GnomAD3 genomes Cov.: 32

GnomAD4 exome Cov.: 31

GnomAD4 genome Cov.: 32

ClinVar

Significance: Pathogenic

Submissions summary: Pathogenic:9

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

Neurofibromatosis, type 1 Pathogenic:2

Jun 12, 2024

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This sequence change affects an acceptor splice site in intron 8 of the NF1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and likely results in a shortened protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with neurofibromatosis type 1 (PMID: 10076878, 30308447, 31730495). In at least one individual the variant was observed to be de novo. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 237610). Studies have shown that disruption of this splice site results in skipping of exon 9, but is expected to preserve the integrity of the reading-frame (PMID: 10076878, 18546366). For these reasons, this variant has been classified as Pathogenic. -

Nov 19, 2024

NHS Central & South Genomic Laboratory Hub

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

not provided Pathogenic:2

Nov 25, 2022

GeneDx

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Intronic variant predicted to result in an in-frame deletion of exon 9 and has been confirmed via RT-PCR (Klose 1999, Pros 2008, Xu 2014); Deletions involving coding exons of this gene are a known mechanism of disease (HGMD); Not observed in large population cohorts (gnomAD); Also known as IVS6-2A>G; This variant is associated with the following publications: (PMID: 25525159, 24789688, 10076878, 30530636, 30308447, 31730495, 22155606, 14722917, 10712197, 18546366, 21280148, 26969325) -

Oct 09, 2018

Athena Diagnostics

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The variant disrupts a canonical splice site, and is therefore predicted to significantly disrupt the protein structure. Found in at least one symptomatic patient, and not found in general population data. -

not specified Pathogenic:1

Dec 04, 2018

ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The NF1 c.889-2A>G variant (rs878853922) is reported in the literature in multiple individuals affected with neurofibromatosis type 1 (Klose 1999, Messiaen 2011, Xu 2014). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 237610), and is absent from general population databases (1000 Genomes Project, Exome Variant Server, and Genome Aggregation Database), indicating it is not a common polymorphism. This variant disrupts the canonical splice acceptor site of intron 8, which is likely to disrupt gene function, and in vitro functional analyses demonstrate skipping of exon 7 (Klose 1999, Pros 2008, Xu 2014). Based on available information, the c.889-2A>G variant is considered to be pathogenic. References: Klose A et al. Two independent mutations in a family with neurofibromatosis type 1 (NF1). Am J Med Genet. 1999 Mar 5;83(1):6-12. Messiaen L et al. Mosaic type-1 NF1 microdeletions as a cause of both generalized and segmental neurofibromatosis type-1 (NF1). Hum Mutat. 2011 Feb;32(2):213-9. Pros E et al. Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Hum Mutat. 2008 Sep;29(9):E173-93. Xu W et al. Fifty-four novel mutations in the NF1 gene and integrated analyses of the mutations that modulate splicing. Int J Mol Med. 2014 Jul;34(1):53-60. -

NF1-related disorder Pathogenic:1

Jul 24, 2024

PreventionGenetics, part of Exact Sciences

Significance: Pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

The NF1 c.889-2A>G variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in multiple individuals with neurofibromatosis type 1 (NF1) (Klose et al. 1999. PubMed ID: 10076878; Tsipi et al. 2018. PubMed ID: 30308447; Table S1 – Assunto et al. 2019. PubMed ID: 31730495), including one individual with NF1 and breast cancer (Frayling et al. 2019. PubMed ID: 30530636). In one individual the variant was reported to be de novo (Tsipi et al. 2018. PubMed ID: 30308447). Functional studies demonstrated this variant results in exon skipping (Klose et al. 1999. PubMed ID: 10076878). Variants that disrupt the consensus splice acceptor site in NF1 are expected to be pathogenic and multiple nucleotide substitutions affecting this splice site (c.889-2A>C, c.889-1G>A) have been reported in individuals with NF1 (Pros et al. 2008. PubMed ID: 18546366; Xu et al. 2014. PubMed ID: 24789688). This variant has not been reported in a large population database, indicating this variant is rare. In ClinVar, nearly all labs have interpreted this variant as pathogenic (https://www.ncbi.nlm.nih.gov/clinvar/variation/237610/). This variant is interpreted as pathogenic. -

Neurofibromatosis, type 1;C0349639:Juvenile myelomonocytic leukemia;C0553586:Café-au-lait macules with pulmonary stenosis;C1834235:Neurofibromatosis, familial spinal;C2931482:Neurofibromatosis-Noonan syndrome Pathogenic:1

-

Juno Genomics, Hangzhou Juno Genomics, Inc

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

PM2_Supporting+PVS1_Strong+PS4_Moderate+PM6+PP4+PP1 -

Juvenile myelomonocytic leukemia Pathogenic:1

Dec 02, 2022

Baylor Genetics

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome;CN230736:Cardiovascular phenotype Pathogenic:1

Jun 22, 2018

Ambry Genetics

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The c.889-2A>G intronic pathogenic mutation results from an A to G substitution two nucleotides upstream from coding exon 9 in the NF1 gene. This mutation has been identified in multiple individuals and families with neurofibromatosis type 1 (NF1), and has been shown via RT-PCR studies to cause aberrant splicing leading to the skipping of exon 7 (coding exon 9) (Klose A et al. Am. J. Med. Genet., 1999 Mar;83:6-12; Pros E et al. Hum. Mutat., 2008 Sep;29:E173-93; Messiaen L et al. Hum. Mutat., 2011 Feb;32:213-9; Xu W et al. Int. J. Mol. Med., 2014 Jul;34:53-60). In addition to the clinical data presented in the literature, alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as a disease-causing mutation. -

Computational scores

Source: dbNSFP v4.3

Name	Calibrated prediction	Score	Prediction
BayesDel_addAF	Pathogenic	0.36	D
BayesDel_noAF	Pathogenic	0.28
CADD	Pathogenic	30
DANN	Uncertain	0.99
Eigen	Pathogenic	1.1
Eigen_PC	Pathogenic	0.94
FATHMM_MKL	Pathogenic	0.99	D
PhyloP100		8.6
GERP RS		5.2
PromoterAI		-0.012	Neutral
Mutation Taster		=0/100	disease causing (ClinVar)

Splicing

Name	Calibrated prediction	Score	Prediction
dbscSNV1_ADA	Pathogenic	1.0
dbscSNV1_RF	Pathogenic	0.94
SpliceAI score (max)		0.87		Details are displayed if max score is > 0.2
DS_AL_spliceai		0.87		Position offset: 2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Other links and lift over

dbSNP: rs878853922; hg19: chr17-29527438;